Demographics (2)
- age_onset - Disease onset age (phv00218108.v1.p1)
- sex - Gender of participant (phv00218111.v1.p1)
Other (18)
- ANALYTE_TYPE - Analyte Type (phv00218115.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00218114.v1.p1)
- CD38 - Molecular Prognostic marker in CLL - CD38 (phv00218110.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00218103.v1.p1)
- FIRST LINE_TUMOR TREATMENT - First line therapy given in each case (phv00218119.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00218117.v1.p1)
- IGHV mutation status - IGHV locus mutation status (phv00218112.v1.p1)
- IS_TUMOR - Tumor status (phv00218116.v1.p1)
- SAMPLE SEQUENCE - Sample obtained sequentially from Subjects (phv00218118.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00218113.v1.p1)
- SAMPLE_ID - Sample ID (phv00218105.v1.p1)
- SAMPLE_USE - Sample Use (phv00218106.v1.p1)
- SECONDARY TUMOR_TREATMENT - Seondary therapy provided after relapse (phv00218120.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00218121.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00218107.v1.p1)
- SUBJECT_ID - Subject ID (phv00218104.v1.p1)
- SUBJECT_ID - Subject ID (phv00218102.v1.p1)
- ZAP 70 - Molecular Prognostic marker in CLL - ZAP 70 (phv00218109.v1.p1)